Molecular Diagnostics Market By Type (Instruments, Reagents, Software & Services), By Technology (Polymerase Chain Reaction (PCR), Hybridization, DNA sequencing, Microarray, Isothermal Nucleic Acid Amplification Technology (INAAT), Others), By Application

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $3,961	256 Pages	Allied Market Research	March, 2022	ALMR17334427

Best Price Guarantee
Price	from $3,961
Length	256 Pages
Publisher	Allied Market Research
Published Date	March, 2022
SKU	ALMR17334427

Molecular Diagnostics Market By Type (Instruments, Reagents, Software & Services), By Technology (Polymerase Chain Reaction (PCR), Hybridization, DNA sequencing, Microarray, Isothermal Nucleic Acid Amplification Technology (INAAT), Others), By Application (Infectious diseases, Oncology, Genetic testing, Blood screening, Others), By End User (Hospital, Reference Labortories, Others): Global Opportunity Analysis and Industry Forecast, 2020-2030

The global molecular diagnostics market was valued at $9,160.61 million in 2020 and is projected to reach $23,905.56 million by 2030, registering a CAGR of 9.86% from 2021 to 2030.

Molecular diagnosis is a process to identify a disease at the molecular level, such as proteins, DNA, and RNA, in a tissue or fluid. Certain tools are used to detect specific sequences in DNA or RNA that may or may not be associated with the disease, which include single nucleotide polymorphism (SNP), deletions, rearrangements, insertions, and others, which are used for diagnosis and prediction of the various infectious diseases, cancer, and other genetic disorders.

The main driving factors that drive the growth of the molecular diagnostics market include, increase in prevalence of cancer, infectious disease, and genetic disorders and increase in awareness about early diagnosis of these diseases among population.

In addition, increase in awareness and acceptance of personalized medicines and growth in the biomarker identification, further supplement the global molecular diagnostics market growth.

Conversely, stringent regulatory requirements for the approval of new molecular diagnostics techniques are expected to obstruct the growth of the market during forecast years. On the other hand, increase in adoption of the molecular diagnostics in the emerging economies is are expected to offer profitable opportunities for the growth of the market during the forecast period.

The molecular diagnostics market is segmented on the basis of product type, technology, application, end user, and region to provide a detailed assessment of the market. By product type, it is bifurcated into instruments, reagents, and software and services. By technology, it is segmented into polymerase chain reaction (PCR), DNA Sequencing, hybridization, microarray, isothermal nucleic acid amplification technology (INAAT), and other techniques include electrophoresis, mass spectroscopy, and flow cytometry. By application, it is divided into infectious diseases, oncology, genetic tests, blood screening, and others include microbiology, cardiovascular diseases, and neurological diseases. Based on end user, it is segmented into, hospitals, reference laboratories, and others include blood banks, home health agencies, and nursing homes. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key market players profiled in the report include F. Hoffmann-La Roche AG, BioMérieux SA, Abbott Laboratories, Becton, Dickinson and Company, Qiagen N.V., Hologic Corporation, Danaher Corporation, S.A., Agilent Inc., Siemens Healthcare GmbH, and Grifols.

KEY BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the global molecular diagnostics market along with the current trends and future estimations to elucidate the imminent investment pockets.
A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the key segments of the industry helps to understand the application and products of molecular diagnostics used across the globe.
Key market players and their strategies have been analyzed to understand the competitive outlook of the market.

Key Market Segments

By Technology

Polymerase Chain Reaction (PCR)
Hybridization
DNA sequencing
Microarray
Isothermal Nucleic Acid Amplification Technology (INAAT)
Others

By Application

Infectious diseases
Oncology
Genetic testing
Blood screening
Others

By Type

Instruments
Reagents
Software Services

By End User

Hospital
Reference Labortories
Others

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Asia-Pacific
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

Key Market Players

ABBOTT LABORATORIES
Agilent Technologies Inc.
BECTON DICKINSON AND COMPANY
BIOMÉRIEUX SA
DANAHER CORPORATION
F. HOFFMON LA-ROCHE LTD
GRIFOLS S.A
HOLOGIC INC.
QIAGEN INC
SIEMENS AG (SIEMENS HEALTHINEERS)

CHAPTER 1:INTRODUCTION: 1.1.Report description; 1.2.Key market segments; 1.3.Key benefits to the stakeholders; 1.4.Research Methodology; 1.4.1.Secondary research; 1.4.2.Primary research; 1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY: 2.1.Key findings of the study; 2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW: 3.1.Market definition and scope; 3.2.Key findings; 3.2.1.Top investment pockets; 3.3.Porter’s five forces analysis; 3.4.Top player positioning; 3.5.Market dynamics; 3.5.1.Drivers; 3.5.2.Restraints; 3.5.3.Opportunities; 3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: MOLECULAR DIAGNOSTICS MARKET, BY TYPE: 4.1 Overview; 4.1.1 Market size and forecast; 4.2 Instruments; 4.2.1 Key market trends, growth factors and opportunities; 4.2.2 Market size and forecast, by region; 4.2.3 Market analysis by country; 4.3 Reagents; 4.3.1 Key market trends, growth factors and opportunities; 4.3.2 Market size and forecast, by region; 4.3.3 Market analysis by country; 4.4 Software & Services; 4.4.1 Key market trends, growth factors and opportunities; 4.4.2 Market size and forecast, by region; 4.4.3 Market analysis by country
CHAPTER 5: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY: 5.1 Overview; 5.1.1 Market size and forecast; 5.2 Polymerase Chain Reaction (PCR); 5.2.1 Key market trends, growth factors and opportunities; 5.2.2 Market size and forecast, by region; 5.2.3 Market analysis by country; 5.3 Hybridization; 5.3.1 Key market trends, growth factors and opportunities; 5.3.2 Market size and forecast, by region; 5.3.3 Market analysis by country; 5.4 DNA sequencing; 5.4.1 Key market trends, growth factors and opportunities; 5.4.2 Market size and forecast, by region; 5.4.3 Market analysis by country; 5.5 Microarray; 5.5.1 Key market trends, growth factors and opportunities; 5.5.2 Market size and forecast, by region; 5.5.3 Market analysis by country; 5.6 Isothermal Nucleic Acid Amplification Technology (INAAT); 5.6.1 Key market trends, growth factors and opportunities; 5.6.2 Market size and forecast, by region; 5.6.3 Market analysis by country; 5.7 Others; 5.7.1 Key market trends, growth factors and opportunities; 5.7.2 Market size and forecast, by region; 5.7.3 Market analysis by country
CHAPTER 6: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION: 6.1 Overview; 6.1.1 Market size and forecast; 6.2 Infectious diseases; 6.2.1 Key market trends, growth factors and opportunities; 6.2.2 Market size and forecast, by region; 6.2.3 Market analysis by country; 6.3 Oncology; 6.3.1 Key market trends, growth factors and opportunities; 6.3.2 Market size and forecast, by region; 6.3.3 Market analysis by country; 6.4 Genetic testing; 6.4.1 Key market trends, growth factors and opportunities; 6.4.2 Market size and forecast, by region; 6.4.3 Market analysis by country; 6.5 Blood screening; 6.5.1 Key market trends, growth factors and opportunities; 6.5.2 Market size and forecast, by region; 6.5.3 Market analysis by country; 6.6 Others; 6.6.1 Key market trends, growth factors and opportunities; 6.6.2 Market size and forecast, by region; 6.6.3 Market analysis by country
CHAPTER 7: MOLECULAR DIAGNOSTICS MARKET, BY END USER: 7.1 Overview; 7.1.1 Market size and forecast; 7.2 Hospital; 7.2.1 Key market trends, growth factors and opportunities; 7.2.2 Market size and forecast, by region; 7.2.3 Market analysis by country; 7.3 Reference Labortories; 7.3.1 Key market trends, growth factors and opportunities; 7.3.2 Market size and forecast, by region; 7.3.3 Market analysis by country; 7.4 Others; 7.4.1 Key market trends, growth factors and opportunities; 7.4.2 Market size and forecast, by region; 7.4.3 Market analysis by country
CHAPTER 8: MOLECULAR DIAGNOSTICS MARKET, BY REGION: 8.1 Overview; 8.1.1 Market size and forecast; 8.2 North America; 8.2.1 Key trends and opportunities; 8.2.2 North America Market size and forecast, by Type; 8.2.3 North America Market size and forecast, by Technology; 8.2.4 North America Market size and forecast, by Application; 8.2.5 North America Market size and forecast, by End User; 8.2.6 North America Market size and forecast, by country; 8.2.6.1 U.S.; 8.2.6.1.1 Market size and forecast, by Type; 8.2.6.1.2 Market size and forecast, by Technology; 8.2.6.1.3 Market size and forecast, by Application; 8.2.6.1.4 Market size and forecast, by End User; 8.2.6.2 Canada; 8.2.6.2.1 Market size and forecast, by Type; 8.2.6.2.2 Market size and forecast, by Technology; 8.2.6.2.3 Market size and forecast, by Application; 8.2.6.2.4 Market size and forecast, by End User; 8.2.6.3 Mexico; 8.2.6.3.1 Market size and forecast, by Type; 8.2.6.3.2 Market size and forecast, by Technology; 8.2.6.3.3 Market size and forecast, by Application; 8.2.6.3.4 Market size and forecast, by End User; 8.3 Europe; 8.3.1 Key trends and opportunities; 8.3.2 Europe Market size and forecast, by Type; 8.3.3 Europe Market size and forecast, by Technology; 8.3.4 Europe Market size and forecast, by Application; 8.3.5 Europe Market size and forecast, by End User; 8.3.6 Europe Market size and forecast, by country; 8.3.6.1 Germany; 8.3.6.1.1 Market size and forecast, by Type; 8.3.6.1.2 Market size and forecast, by Technology; 8.3.6.1.3 Market size and forecast, by Application; 8.3.6.1.4 Market size and forecast, by End User; 8.3.6.2 France; 8.3.6.2.1 Market size and forecast, by Type; 8.3.6.2.2 Market size and forecast, by Technology; 8.3.6.2.3 Market size and forecast, by Application; 8.3.6.2.4 Market size and forecast, by End User; 8.3.6.3 U.K.; 8.3.6.3.1 Market size and forecast, by Type; 8.3.6.3.2 Market size and forecast, by Technology; 8.3.6.3.3 Market size and forecast, by Application; 8.3.6.3.4 Market size and forecast, by End User; 8.3.6.4 Italy; 8.3.6.4.1 Market size and forecast, by Type; 8.3.6.4.2 Market size and forecast, by Technology; 8.3.6.4.3 Market size and forecast, by Application; 8.3.6.4.4 Market size and forecast, by End User; 8.3.6.5 Spain; 8.3.6.5.1 Market size and forecast, by Type; 8.3.6.5.2 Market size and forecast, by Technology; 8.3.6.5.3 Market size and forecast, by Application; 8.3.6.5.4 Market size and forecast, by End User; 8.3.6.6 Rest of Asia-Pacific; 8.3.6.6.1 Market size and forecast, by Type; 8.3.6.6.2 Market size and forecast, by Technology; 8.3.6.6.3 Market size and forecast, by Application; 8.3.6.6.4 Market size and forecast, by End User; 8.4 Asia-Pacific; 8.4.1 Key trends and opportunities; 8.4.2 Asia-Pacific Market size and forecast, by Type; 8.4.3 Asia-Pacific Market size and forecast, by Technology; 8.4.4 Asia-Pacific Market size and forecast, by Application; 8.4.5 Asia-Pacific Market size and forecast, by End User; 8.4.6 Asia-Pacific Market size and forecast, by country; 8.4.6.1 China; 8.4.6.1.1 Market size and forecast, by Type; 8.4.6.1.2 Market size and forecast, by Technology; 8.4.6.1.3 Market size and forecast, by Application; 8.4.6.1.4 Market size and forecast, by End User; 8.4.6.2 Japan; 8.4.6.2.1 Market size and forecast, by Type; 8.4.6.2.2 Market size and forecast, by Technology; 8.4.6.2.3 Market size and forecast, by Application; 8.4.6.2.4 Market size and forecast, by End User; 8.4.6.3 India; 8.4.6.3.1 Market size and forecast, by Type; 8.4.6.3.2 Market size and forecast, by Technology; 8.4.6.3.3 Market size and forecast, by Application; 8.4.6.3.4 Market size and forecast, by End User; 8.4.6.4 Australia; 8.4.6.4.1 Market size and forecast, by Type; 8.4.6.4.2 Market size and forecast, by Technology; 8.4.6.4.3 Market size and forecast, by Application; 8.4.6.4.4 Market size and forecast, by End User; 8.4.6.5 South Korea; 8.4.6.5.1 Market size and forecast, by Type; 8.4.6.5.2 Market size and forecast, by Technology; 8.4.6.5.3 Market size and forecast, by Application; 8.4.6.5.4 Market size and forecast, by End User; 8.4.6.6 Rest of Asia-Pacific; 8.4.6.6.1 Market size and forecast, by Type; 8.4.6.6.2 Market size and forecast, by Technology; 8.4.6.6.3 Market size and forecast, by Application; 8.4.6.6.4 Market size and forecast, by End User; 8.5 LAMEA; 8.5.1 Key trends and opportunities; 8.5.2 LAMEA Market size and forecast, by Type; 8.5.3 LAMEA Market size and forecast, by Technology; 8.5.4 LAMEA Market size and forecast, by Application; 8.5.5 LAMEA Market size and forecast, by End User; 8.5.6 LAMEA Market size and forecast, by country; 8.5.6.1 Brazil; 8.5.6.1.1 Market size and forecast, by Type; 8.5.6.1.2 Market size and forecast, by Technology; 8.5.6.1.3 Market size and forecast, by Application; 8.5.6.1.4 Market size and forecast, by End User; 8.5.6.2 Saudi Arabia; 8.5.6.2.1 Market size and forecast, by Type; 8.5.6.2.2 Market size and forecast, by Technology; 8.5.6.2.3 Market size and forecast, by Application; 8.5.6.2.4 Market size and forecast, by End User; 8.5.6.3 South Africa; 8.5.6.3.1 Market size and forecast, by Type; 8.5.6.3.2 Market size and forecast, by Technology; 8.5.6.3.3 Market size and forecast, by Application; 8.5.6.3.4 Market size and forecast, by End User; 8.5.6.4 Rest of LAMEA; 8.5.6.4.1 Market size and forecast, by Type; 8.5.6.4.2 Market size and forecast, by Technology; 8.5.6.4.3 Market size and forecast, by Application; 8.5.6.4.4 Market size and forecast, by End User
CHAPTER 9: COMPANY LANDSCAPE: 9.1. Introduction; 9.2. Top winning strategies; 9.3. Product Mapping of Top 10 Player; 9.4. Competitive Dashboard; 9.5. Competitive Heatmap; 9.6. Key developments
CHAPTER 10: COMPANY PROFILES: 10.1 ABBOTT LABORATORIES; 10.1.1 Company overview; 10.1.2 Company snapshot; 10.1.3 Operating business segments; 10.1.4 Product portfolio; 10.1.5 Business performance; 10.1.6 Key strategic moves and developments; 10.2 Agilent Technologies Inc.; 10.2.1 Company overview; 10.2.2 Company snapshot; 10.2.3 Operating business segments; 10.2.4 Product portfolio; 10.2.5 Business performance; 10.2.6 Key strategic moves and developments; 10.3 BECTON DICKINSON AND COMPANY; 10.3.1 Company overview; 10.3.2 Company snapshot; 10.3.3 Operating business segments; 10.3.4 Product portfolio; 10.3.5 Business performance; 10.3.6 Key strategic moves and developments; 10.4 BIOMÉRIEUX SA; 10.4.1 Company overview; 10.4.2 Company snapshot; 10.4.3 Operating business segments; 10.4.4 Product portfolio; 10.4.5 Business performance; 10.4.6 Key strategic moves and developments; 10.5 DANAHER CORPORATION; 10.5.1 Company overview; 10.5.2 Company snapshot; 10.5.3 Operating business segments; 10.5.4 Product portfolio; 10.5.5 Business performance; 10.5.6 Key strategic moves and developments; 10.6 F. HOFFMON LA-ROCHE LTD; 10.6.1 Company overview; 10.6.2 Company snapshot; 10.6.3 Operating business segments; 10.6.4 Product portfolio; 10.6.5 Business performance; 10.6.6 Key strategic moves and developments; 10.7 GRIFOLS S.A; 10.7.1 Company overview; 10.7.2 Company snapshot; 10.7.3 Operating business segments; 10.7.4 Product portfolio; 10.7.5 Business performance; 10.7.6 Key strategic moves and developments; 10.8 HOLOGIC INC.; 10.8.1 Company overview; 10.8.2 Company snapshot; 10.8.3 Operating business segments; 10.8.4 Product portfolio; 10.8.5 Business performance; 10.8.6 Key strategic moves and developments; 10.9 QIAGEN INC; 10.9.1 Company overview; 10.9.2 Company snapshot; 10.9.3 Operating business segments; 10.9.4 Product portfolio; 10.9.5 Business performance; 10.9.6 Key strategic moves and developments; 10.10 SIEMENS AG (SIEMENS HEALTHINEERS); 10.10.1 Company overview; 10.10.2 Company snapshot; 10.10.3 Operating business segments; 10.10.4 Product portfolio; 10.10.5 Business performance; 10.10.6 Key strategic moves and developments
LIST OF TABLES: TABLE 1. GLOBAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2020-2030,($MILLION); TABLE 2. MOLECULAR DIAGNOSTICS MARKET REVENUE, FOR INSTRUMENTS, BY REGION , 2020-2030,($MILLION); TABLE 3. MOLECULAR DIAGNOSTICS MARKET INSTRUMENTS BY COUNTRY, 2020-2030,($MILLION); TABLE 4. MOLECULAR DIAGNOSTICS MARKET REVENUE, FOR REAGENTS, BY REGION , 2020-2030,($MILLION); TABLE 5. MOLECULAR DIAGNOSTICS MARKET REAGENTS BY COUNTRY, 2020-2030,($MILLION); TABLE 6. MOLECULAR DIAGNOSTICS MARKET REVENUE, FOR SOFTWARE & SERVICES, BY REGION , 2020-2030,($MILLION); TABLE 7. MOLECULAR DIAGNOSTICS MARKET SOFTWARE & SERVICES BY COUNTRY, 2020-2030,($MILLION); TABLE 8. GLOBAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2030,($MILLION); TABLE 9. MOLECULAR DIAGNOSTICS MARKET REVENUE, FOR POLYMERASE CHAIN REACTION (PCR), BY REGION , 2020-2030,($MILLION); TABLE 10. MOLECULAR DIAGNOSTICS MARKET POLYMERASE CHAIN REACTION (PCR) BY COUNTRY, 2020-2030,($MILLION); TABLE 11. MOLECULAR DIAGNOSTICS MARKET REVENUE, FOR HYBRIDIZATION, BY REGION , 2020-2030,($MILLION); TABLE 12. MOLECULAR DIAGNOSTICS MARKET HYBRIDIZATION BY COUNTRY, 2020-2030,($MILLION); TABLE 13. MOLECULAR DIAGNOSTICS MARKET REVENUE, FOR DNA SEQUENCING, BY REGION , 2020-2030,($MILLION); TABLE 14. MOLECULAR DIAGNOSTICS MARKET DNA SEQUENCING BY COUNTRY, 2020-2030,($MILLION); TABLE 15. MOLECULAR DIAGNOSTICS MARKET REVENUE, FOR MICROARRAY, BY REGION , 2020-2030,($MILLION); TABLE 16. MOLECULAR DIAGNOSTICS MARKET MICROARRAY BY COUNTRY, 2020-2030,($MILLION); TABLE 17. MOLECULAR DIAGNOSTICS MARKET REVENUE, FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT), BY REGION , 2020-2030,($MILLION); TABLE 18. MOLECULAR DIAGNOSTICS MARKET ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT) BY COUNTRY, 2020-2030,($MILLION); TABLE 19. MOLECULAR DIAGNOSTICS MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION); TABLE 20. MOLECULAR DIAGNOSTICS MARKET OTHERS BY COUNTRY, 2020-2030,($MILLION); TABLE 21. GLOBAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020-2030,($MILLION); TABLE 22. MOLECULAR DIAGNOSTICS MARKET REVENUE, FOR INFECTIOUS DISEASES, BY REGION , 2020-2030,($MILLION); TABLE 23. MOLECULAR DIAGNOSTICS MARKET INFECTIOUS DISEASES BY COUNTRY, 2020-2030,($MILLION); TABLE 24. MOLECULAR DIAGNOSTICS MARKET REVENUE, FOR ONCOLOGY, BY REGION , 2020-2030,($MILLION); TABLE 25. MOLECULAR DIAGNOSTICS MARKET ONCOLOGY BY COUNTRY, 2020-2030,($MILLION); TABLE 26. MOLECULAR DIAGNOSTICS MARKET REVENUE, FOR GENETIC TESTING, BY REGION , 2020-2030,($MILLION); TABLE 27. MOLECULAR DIAGNOSTICS MARKET GENETIC TESTING BY COUNTRY, 2020-2030,($MILLION); TABLE 28. MOLECULAR DIAGNOSTICS MARKET REVENUE, FOR BLOOD SCREENING, BY REGION , 2020-2030,($MILLION); TABLE 29. MOLECULAR DIAGNOSTICS MARKET BLOOD SCREENING BY COUNTRY, 2020-2030,($MILLION); TABLE 30. MOLECULAR DIAGNOSTICS MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION); TABLE 31. MOLECULAR DIAGNOSTICS MARKET OTHERS BY COUNTRY, 2020-2030,($MILLION); TABLE 32. GLOBAL MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020-2030,($MILLION); TABLE 33. MOLECULAR DIAGNOSTICS MARKET REVENUE, FOR HOSPITAL, BY REGION , 2020-2030,($MILLION); TABLE 34. MOLECULAR DIAGNOSTICS MARKET HOSPITAL BY COUNTRY, 2020-2030,($MILLION); TABLE 35. MOLECULAR DIAGNOSTICS MARKET REVENUE, FOR REFERENCE LABORTORIES, BY REGION , 2020-2030,($MILLION); TABLE 36. MOLECULAR DIAGNOSTICS MARKET REFERENCE LABORTORIES BY COUNTRY, 2020-2030,($MILLION); TABLE 37. MOLECULAR DIAGNOSTICS MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION); TABLE 38. MOLECULAR DIAGNOSTICS MARKET OTHERS BY COUNTRY, 2020-2030,($MILLION); TABLE 39. MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2020-2030,($MILLION); TABLE 40. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2020-2030,($MILLION); TABLE 41. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2030,($MILLION); TABLE 42. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020-2030,($MILLION); TABLE 43. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020-2030,($MILLION); TABLE 44. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2020-2030,($MILLION); TABLE 45. U.S. MOLECULAR DIAGNOSTICS MARKET BY TYPE 2020-2030,($MILLION); TABLE 46. U.S. MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2020-2030,($MILLION); TABLE 47. U.S. MOLECULAR DIAGNOSTICS MARKET BY APPLICATION 2020-2030,($MILLION); TABLE 48. U.S. MOLECULAR DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION); TABLE 49. CANADA MOLECULAR DIAGNOSTICS MARKET BY TYPE 2020-2030,($MILLION); TABLE 50. CANADA MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2020-2030,($MILLION); TABLE 51. CANADA MOLECULAR DIAGNOSTICS MARKET BY APPLICATION 2020-2030,($MILLION); TABLE 52. CANADA MOLECULAR DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION); TABLE 53. MEXICO MOLECULAR DIAGNOSTICS MARKET BY TYPE 2020-2030,($MILLION); TABLE 54. MEXICO MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2020-2030,($MILLION); TABLE 55. MEXICO MOLECULAR DIAGNOSTICS MARKET BY APPLICATION 2020-2030,($MILLION); TABLE 56. MEXICO MOLECULAR DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION); TABLE 57. EUROPE MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2020-2030,($MILLION); TABLE 58. EUROPE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2030,($MILLION); TABLE 59. EUROPE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020-2030,($MILLION); TABLE 60. EUROPE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020-2030,($MILLION); TABLE 61. EUROPE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2020-2030,($MILLION); TABLE 62. GERMANY MOLECULAR DIAGNOSTICS MARKET BY TYPE 2020-2030,($MILLION); TABLE 63. GERMANY MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2020-2030,($MILLION); TABLE 64. GERMANY MOLECULAR DIAGNOSTICS MARKET BY APPLICATION 2020-2030,($MILLION); TABLE 65. GERMANY MOLECULAR DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION); TABLE 66. FRANCE MOLECULAR DIAGNOSTICS MARKET BY TYPE 2020-2030,($MILLION); TABLE 67. FRANCE MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2020-2030,($MILLION); TABLE 68. FRANCE MOLECULAR DIAGNOSTICS MARKET BY APPLICATION 2020-2030,($MILLION); TABLE 69. FRANCE MOLECULAR DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION); TABLE 70. U.K. MOLECULAR DIAGNOSTICS MARKET BY TYPE 2020-2030,($MILLION); TABLE 71. U.K. MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2020-2030,($MILLION); TABLE 72. U.K. MOLECULAR DIAGNOSTICS MARKET BY APPLICATION 2020-2030,($MILLION); TABLE 73. U.K. MOLECULAR DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION); TABLE 74. ITALY MOLECULAR DIAGNOSTICS MARKET BY TYPE 2020-2030,($MILLION); TABLE 75. ITALY MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2020-2030,($MILLION); TABLE 76. ITALY MOLECULAR DIAGNOSTICS MARKET BY APPLICATION 2020-2030,($MILLION); TABLE 77. ITALY MOLECULAR DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION); TABLE 78. SPAIN MOLECULAR DIAGNOSTICS MARKET BY TYPE 2020-2030,($MILLION); TABLE 79. SPAIN MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2020-2030,($MILLION); TABLE 80. SPAIN MOLECULAR DIAGNOSTICS MARKET BY APPLICATION 2020-2030,($MILLION); TABLE 81. SPAIN MOLECULAR DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION); TABLE 82. REST OF ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET BY TYPE 2020-2030,($MILLION); TABLE 83. REST OF ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2020-2030,($MILLION); TABLE 84. REST OF ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET BY APPLICATION 2020-2030,($MILLION); TABLE 85. REST OF ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION); TABLE 86. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2020-2030,($MILLION); TABLE 87. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2030,($MILLION); TABLE 88. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020-2030,($MILLION); TABLE 89. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020-2030,($MILLION); TABLE 90. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2020-2030,($MILLION); TABLE 91. CHINA MOLECULAR DIAGNOSTICS MARKET BY TYPE 2020-2030,($MILLION); TABLE 92. CHINA MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2020-2030,($MILLION); TABLE 93. CHINA MOLECULAR DIAGNOSTICS MARKET BY APPLICATION 2020-2030,($MILLION); TABLE 94. CHINA MOLECULAR DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION); TABLE 95. JAPAN MOLECULAR DIAGNOSTICS MARKET BY TYPE 2020-2030,($MILLION); TABLE 96. JAPAN MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2020-2030,($MILLION); TABLE 97. JAPAN MOLECULAR DIAGNOSTICS MARKET BY APPLICATION 2020-2030,($MILLION); TABLE 98. JAPAN MOLECULAR DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION); TABLE 99. INDIA MOLECULAR DIAGNOSTICS MARKET BY TYPE 2020-2030,($MILLION); TABLE 100. INDIA MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2020-2030,($MILLION); TABLE 101. INDIA MOLECULAR DIAGNOSTICS MARKET BY APPLICATION 2020-2030,($MILLION); TABLE 102. INDIA MOLECULAR DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION); TABLE 103. AUSTRALIA MOLECULAR DIAGNOSTICS MARKET BY TYPE 2020-2030,($MILLION); TABLE 104. AUSTRALIA MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2020-2030,($MILLION); TABLE 105. AUSTRALIA MOLECULAR DIAGNOSTICS MARKET BY APPLICATION 2020-2030,($MILLION); TABLE 106. AUSTRALIA MOLECULAR DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION); TABLE 107. SOUTH KOREA MOLECULAR DIAGNOSTICS MARKET BY TYPE 2020-2030,($MILLION); TABLE 108. SOUTH KOREA MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2020-2030,($MILLION); TABLE 109. SOUTH KOREA MOLECULAR DIAGNOSTICS MARKET BY APPLICATION 2020-2030,($MILLION); TABLE 110. SOUTH KOREA MOLECULAR DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION); TABLE 111. REST OF ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET BY TYPE 2020-2030,($MILLION); TABLE 112. REST OF ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2020-2030,($MILLION); TABLE 113. REST OF ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET BY APPLICATION 2020-2030,($MILLION); TABLE 114. REST OF ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION); TABLE 115. LAMEA MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2020-2030,($MILLION); TABLE 116. LAMEA MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2030,($MILLION); TABLE 117. LAMEA MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020-2030,($MILLION); TABLE 118. LAMEA MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020-2030,($MILLION); TABLE 119. LAMEA MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2020-2030,($MILLION); TABLE 120. BRAZIL MOLECULAR DIAGNOSTICS MARKET BY TYPE 2020-2030,($MILLION); TABLE 121. BRAZIL MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2020-2030,($MILLION); TABLE 122. BRAZIL MOLECULAR DIAGNOSTICS MARKET BY APPLICATION 2020-2030,($MILLION); TABLE 123. BRAZIL MOLECULAR DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION); TABLE 124. SAUDI ARABIA MOLECULAR DIAGNOSTICS MARKET BY TYPE 2020-2030,($MILLION); TABLE 125. SAUDI ARABIA MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2020-2030,($MILLION); TABLE 126. SAUDI ARABIA MOLECULAR DIAGNOSTICS MARKET BY APPLICATION 2020-2030,($MILLION); TABLE 127. SAUDI ARABIA MOLECULAR DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION); TABLE 128. SOUTH AFRICA MOLECULAR DIAGNOSTICS MARKET BY TYPE 2020-2030,($MILLION); TABLE 129. SOUTH AFRICA MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2020-2030,($MILLION); TABLE 130. SOUTH AFRICA MOLECULAR DIAGNOSTICS MARKET BY APPLICATION 2020-2030,($MILLION); TABLE 131. SOUTH AFRICA MOLECULAR DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION); TABLE 132. REST OF LAMEA MOLECULAR DIAGNOSTICS MARKET BY TYPE 2020-2030,($MILLION); TABLE 133. REST OF LAMEA MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2020-2030,($MILLION); TABLE 134. REST OF LAMEA MOLECULAR DIAGNOSTICS MARKET BY APPLICATION 2020-2030,($MILLION); TABLE 135. REST OF LAMEA MOLECULAR DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION); TABLE 136.ABBOTT LABORATORIES: COMPANY SNAPSHOT; TABLE 137.ABBOTT LABORATORIES: OPERATING SEGMENTS; TABLE 138.ABBOTT LABORATORIES: PRODUCT PORTFOLIO; TABLE 139.ABBOTT LABORATORIES: NET SALES,; TABLE 140.ABBOTT LABORATORIES: KEY STRATERGIES; TABLE 141.AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT; TABLE 142.AGILENT TECHNOLOGIES INC.: OPERATING SEGMENTS; TABLE 143.AGILENT TECHNOLOGIES INC.: PRODUCT PORTFOLIO; TABLE 144.AGILENT TECHNOLOGIES INC.: NET SALES,; TABLE 145.AGILENT TECHNOLOGIES INC.: KEY STRATERGIES; TABLE 146.BECTON DICKINSON AND COMPANY: COMPANY SNAPSHOT; TABLE 147.BECTON DICKINSON AND COMPANY: OPERATING SEGMENTS; TABLE 148.BECTON DICKINSON AND COMPANY: PRODUCT PORTFOLIO; TABLE 149.BECTON DICKINSON AND COMPANY: NET SALES,; TABLE 150.BECTON DICKINSON AND COMPANY: KEY STRATERGIES; TABLE 151.BIOMÉRIEUX SA: COMPANY SNAPSHOT; TABLE 152.BIOMÉRIEUX SA: OPERATING SEGMENTS; TABLE 153.BIOMÉRIEUX SA: PRODUCT PORTFOLIO; TABLE 154.BIOMÉRIEUX SA: NET SALES,; TABLE 155.BIOMÉRIEUX SA: KEY STRATERGIES; TABLE 156.DANAHER CORPORATION: COMPANY SNAPSHOT; TABLE 157.DANAHER CORPORATION: OPERATING SEGMENTS; TABLE 158.DANAHER CORPORATION: PRODUCT PORTFOLIO; TABLE 159.DANAHER CORPORATION: NET SALES,; TABLE 160.DANAHER CORPORATION: KEY STRATERGIES; TABLE 161.F. HOFFMON LA-ROCHE LTD: COMPANY SNAPSHOT; TABLE 162.F. HOFFMON LA-ROCHE LTD: OPERATING SEGMENTS; TABLE 163.F. HOFFMON LA-ROCHE LTD: PRODUCT PORTFOLIO; TABLE 164.F. HOFFMON LA-ROCHE LTD: NET SALES,; TABLE 165.F. HOFFMON LA-ROCHE LTD: KEY STRATERGIES; TABLE 166.GRIFOLS S.A: COMPANY SNAPSHOT; TABLE 167.GRIFOLS S.A: OPERATING SEGMENTS; TABLE 168.GRIFOLS S.A: PRODUCT PORTFOLIO; TABLE 169.GRIFOLS S.A: NET SALES,; TABLE 170.GRIFOLS S.A: KEY STRATERGIES; TABLE 171.HOLOGIC INC.: COMPANY SNAPSHOT; TABLE 172.HOLOGIC INC.: OPERATING SEGMENTS; TABLE 173.HOLOGIC INC.: PRODUCT PORTFOLIO; TABLE 174.HOLOGIC INC.: NET SALES,; TABLE 175.HOLOGIC INC.: KEY STRATERGIES; TABLE 176.QIAGEN INC: COMPANY SNAPSHOT; TABLE 177.QIAGEN INC: OPERATING SEGMENTS; TABLE 178.QIAGEN INC: PRODUCT PORTFOLIO; TABLE 179.QIAGEN INC: NET SALES,; TABLE 180.QIAGEN INC: KEY STRATERGIES; TABLE 181.SIEMENS AG (SIEMENS HEALTHINEERS): COMPANY SNAPSHOT; TABLE 182.SIEMENS AG (SIEMENS HEALTHINEERS): OPERATING SEGMENTS; TABLE 183.SIEMENS AG (SIEMENS HEALTHINEERS): PRODUCT PORTFOLIO; TABLE 184.SIEMENS AG (SIEMENS HEALTHINEERS): NET SALES,; TABLE 185.SIEMENS AG (SIEMENS HEALTHINEERS): KEY STRATERGIES
LIST OF FIGURES: FIGURE 1.MOLECULAR DIAGNOSTICS MARKET SEGMENTATION; FIGURE 2.MOLECULAR DIAGNOSTICS MARKET,2020-2030; FIGURE 3.MOLECULAR DIAGNOSTICS MARKET,2020-2030; FIGURE 4. TOP INVESTMENT POCKETS, BY REGION; FIGURE 5.PORTER FIVE-1; FIGURE 6.PORTER FIVE-2; FIGURE 7.PORTER FIVE-3; FIGURE 8.PORTER FIVE-4; FIGURE 9.PORTER FIVE-5; FIGURE 10.TOP PLAYER POSITIONING; FIGURE 11.MOLECULAR DIAGNOSTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES; FIGURE 11.MOLECULAR DIAGNOSTICS MARKET,BY TYPE,2020(%); FIGURE 12.COMPARATIVE SHARE ANALYSIS OF INSTRUMENTS MOLECULAR DIAGNOSTICS MARKET,2020-2030(%); FIGURE 13.COMPARATIVE SHARE ANALYSIS OF REAGENTS MOLECULAR DIAGNOSTICS MARKET,2020-2030(%); FIGURE 14.COMPARATIVE SHARE ANALYSIS OF SOFTWARE & SERVICES MOLECULAR DIAGNOSTICS MARKET,2020-2030(%); FIGURE 15.MOLECULAR DIAGNOSTICS MARKET,BY TECHNOLOGY,2020(%); FIGURE 16.COMPARATIVE SHARE ANALYSIS OF POLYMERASE CHAIN REACTION (PCR) MOLECULAR DIAGNOSTICS MARKET,2020-2030(%); FIGURE 17.COMPARATIVE SHARE ANALYSIS OF HYBRIDIZATION MOLECULAR DIAGNOSTICS MARKET,2020-2030(%); FIGURE 18.COMPARATIVE SHARE ANALYSIS OF DNA SEQUENCING MOLECULAR DIAGNOSTICS MARKET,2020-2030(%); FIGURE 19.COMPARATIVE SHARE ANALYSIS OF MICROARRAY MOLECULAR DIAGNOSTICS MARKET,2020-2030(%); FIGURE 20.COMPARATIVE SHARE ANALYSIS OF ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT) MOLECULAR DIAGNOSTICS MARKET,2020-2030(%); FIGURE 21.COMPARATIVE SHARE ANALYSIS OF OTHERS MOLECULAR DIAGNOSTICS MARKET,2020-2030(%); FIGURE 22.MOLECULAR DIAGNOSTICS MARKET,BY APPLICATION,2020(%); FIGURE 23.COMPARATIVE SHARE ANALYSIS OF INFECTIOUS DISEASES MOLECULAR DIAGNOSTICS MARKET,2020-2030(%); FIGURE 24.COMPARATIVE SHARE ANALYSIS OF ONCOLOGY MOLECULAR DIAGNOSTICS MARKET,2020-2030(%); FIGURE 25.COMPARATIVE SHARE ANALYSIS OF GENETIC TESTING MOLECULAR DIAGNOSTICS MARKET,2020-2030(%); FIGURE 26.COMPARATIVE SHARE ANALYSIS OF BLOOD SCREENING MOLECULAR DIAGNOSTICS MARKET,2020-2030(%); FIGURE 27.COMPARATIVE SHARE ANALYSIS OF OTHERS MOLECULAR DIAGNOSTICS MARKET,2020-2030(%); FIGURE 28.MOLECULAR DIAGNOSTICS MARKET,BY END USER,2020(%); FIGURE 29.COMPARATIVE SHARE ANALYSIS OF HOSPITAL MOLECULAR DIAGNOSTICS MARKET,2020-2030(%); FIGURE 30.COMPARATIVE SHARE ANALYSIS OF REFERENCE LABORTORIES MOLECULAR DIAGNOSTICS MARKET,2020-2030(%); FIGURE 31.COMPARATIVE SHARE ANALYSIS OF OTHERS MOLECULAR DIAGNOSTICS MARKET,2020-2030(%); FIGURE 32.MOLECULAR DIAGNOSTICS MARKET BY REGION,2020; FIGURE 33.U.S. MOLECULAR DIAGNOSTICS MARKET,2020-2030($MILLION); FIGURE 34.CANADA MOLECULAR DIAGNOSTICS MARKET,2020-2030($MILLION); FIGURE 35.MEXICO MOLECULAR DIAGNOSTICS MARKET,2020-2030($MILLION); FIGURE 36.GERMANY MOLECULAR DIAGNOSTICS MARKET,2020-2030($MILLION); FIGURE 37.FRANCE MOLECULAR DIAGNOSTICS MARKET,2020-2030($MILLION); FIGURE 38.U.K. MOLECULAR DIAGNOSTICS MARKET,2020-2030($MILLION); FIGURE 39.ITALY MOLECULAR DIAGNOSTICS MARKET,2020-2030($MILLION); FIGURE 40.SPAIN MOLECULAR DIAGNOSTICS MARKET,2020-2030($MILLION); FIGURE 41.REST OF ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET,2020-2030($MILLION); FIGURE 42.CHINA MOLECULAR DIAGNOSTICS MARKET,2020-2030($MILLION); FIGURE 43.JAPAN MOLECULAR DIAGNOSTICS MARKET,2020-2030($MILLION)